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patterns of sugar moieties displayed on their cell surfaces and neutralising them via an antibody-independent reaction
cascade. While particularly important during early childhood before the adaptive immune system is established, or
when adaptive immunity is compromised, it has a protective function throughout life, neutralising invading pathogens
directly and helping to stimulate and direct an effective immune response. Complement activation is initiated
when complexes comprising mannose-binding lectin (MBL) or serum ﬁcolins and MBL-associated serine protease-2
(MASP-2) bind to pathogens. Binding induces conformational changes in these complexes, leading to autoactivation
of the MASPs, which in turn activate the downstream reaction cascade. A major goal in complement research is to
understand the molecular events that trigger complement activation. Over the last few years, structure–function studies
have improved our knowledge of the way in which MBL binds to MASPs by deﬁning the portions of these proteins
that interact and by solving the structures of key protein fragments. In this review, I will summarise the main ﬁndings
of these studies and describe current theories to explain how the components combine to initiate the reaction cascade.
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The complement cascade is a fundamental component
of the immune system, providing protection against
invading microorganisms through both antibody-depen-
dent and -independent mechanisms (Porter and Reid,
1978). It also mediates many cellular and humoral
interactions within the host, including chemotaxis,
phagocytosis, cell adhesion and B-cell differentiation,
thereby helping to coordinate and direct an effective
immune response (Carroll, 2004). Three different path-
ways initiate the complement cascade: the classical,
alternative and lectin pathways. This review will focus
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ment activation, the most recently discovered and
probably the most ancient of the three activation
pathways (Dodds, 2002).
Similar to the C1 complex of the classical pathway,
the initiating complexes of the lectin pathway comprise
separate recognition and enzyme components. The
recognition components, mannose-binding lectin
(MBL) and serum ﬁcolins, bind directly to sugars or
N-acetyl groups on pathogenic cells and activate three
different enzymes, called MBL-associated serine pro-
teases (MASPs-1 to -3), to activate complement (Turner,
1996; Schwaeble et al., 2002). Currently, only MASP-2
has a clearly deﬁned role in complement activation
(Thiel et al., 1997; Rossi et al., 2001). It initially cleaves
C4 to produce the peptide anaphylatoxin C4a and the
C4b fragment, which attaches to the activating surface
of the pathogen upon exposure of the highly reactive
thioester group. C2 then binds to the immobilised C4b
molecule and is also cleaved by MASP-2 to generate
C2b and C2a. C2a remains attached to C4b to become
the catalytic component of the C3 convertase (C4b2a),
the enzyme that catalyses the next step in the reaction
pathway (Kerr, 1980). The roles of MASP-1 and MASP-
3 are not known. MASP-1 cleaves C2 but not C4, so it
might enhance complement activation triggered by
lectin–MASP-2 complexes, but cannot initiate activa-
tion itself (Chen and Wallis, 2004). The only substrate
that has been identiﬁed for MASP-3 is insulin-like
growth factor-binding protein 5 (Cortesio and Jiang,
2006). However, it is unclear if this is a physiological
substrate.
The importance of the lectin pathway to human
health is highlighted by immunodeﬁciencies associated
with mutations to MBL (Turner, 1996) and MASP-2
(Stengaard-Pedersen et al., 2003). Individuals homo- or
heterozygous for any one of three point mutations in the
MBL gene or with mutations to the promoter region are
susceptible to a wide range of bacterial, viral and
parasitic infections, particularly in early childhood,
before adaptive immunity is established (Sumiya et al.,
1991) or when the adaptive immune response is
compromised, for example, during HIV infection or
following chemotherapy (Garred et al., 1997; Neth et al.,
2001). The lectin pathway also plays a role in the
pathogenesis of inﬂammatory disorders, such as cystic
ﬁbrosis and rheumatoid arthritis, where MBL deﬁciency
is associated with more severe disease (Kilpatrick, 2002).
Because of its key protective roles, MBL is a strong
candidate for clinical trials to reduce susceptibility to
infections or for use as a disease-modifying agent
(Summerﬁeld, 2003).
While complement generally has a protective role,
under certain circumstances, inappropriate activation
causes signiﬁcant host damage. For example, tissues
including heart and kidney are subject to signiﬁcantcomplement-mediated cytotoxicity upon reperfusion of
oxygenated blood following transient ischaemia (Carroll
and Holers, 2005). In several recent studies, the lectin
pathway has been directly implicated in triggering such
inappropriate activation (Hart et al., 2005; Moller-
Kristensen et al., 2005; Walsh et al., 2005). By preventing
host-mediated tissue damage, selective lectin pathway
inhibitors are likely to have important therapeutic
beneﬁts for treatment of common, potentially life-
threatening diseases, including ischaemic heart disease,
kidney disease and reperfusion injuries. Thus, under-
standing how complement activation is initiated and
regulated is of great interest both from a biochemical
perspective and also as a step towards designing
therapeutics to modulate the immune response.Structural organisation of MBL and MASPs
Structural organisation of MBL
MBL consists of large oligomers assembled from
identical polypeptide chains (Drickamer and Taylor,
1993). Three polypeptides assemble into subunits, which
subsequently associate to form larger oligomers. Each
subunit is composed of an N-terminal cysteine-rich
domain followed by a collagenous domain, an a-helical
coiled coil or neck region and three C-terminal C-type
carbohydrate-recognition domains (CRDs) (Fig. 1A).
Interchain disulphide bonds link the N-terminal do-
mains of polypeptides together both within and between
subunits to stabilise oligomers (Wallis and Drickamer,
1999). Although the compositions of MBL oligomers
are generally similar in different species, there are some
differences. For example, human MBL comprises
dimers to hexamers of subunits of which trimers and
tetramers are probably the predominant species (Lu
et al., 1990; Teillet et al., 2005), while rat MBL is mainly
composed of dimers, trimers and tetramers of subunits
(Wallis and Drickamer, 1999).
Heterogeneity in MBL probably arises because of the
way in which oligomers assemble within the endoplas-
mic reticulum of liver cells during biosynthesis. Pulse-
chase experiments show that while individual MBL
subunits assemble rapidly, the protein matures into the
larger oligomeric forms more slowly as it moves to the
cell surface for secretion (Heise et al., 2000). A key
factor controlling the sizes of oligomers appears to be
the pattern of disulphide bonds at the N-terminal ends
of subunits. Each polypeptide in human MBL has three
cysteine residues within this region that can potentially
form disulphide bonds. Certain bonding patterns allow
interchain bonds to two additional subunits and are thus
compatible with further oligomerisation, whereas other
patterns permit linkage to only one subunit, therefore
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Fig. 1. Domain organisation of MBL and MASPs. (A)
Structural organisation of MBL. The collagenous domain is
shown as two segments, which are separated by the interrup-
tion in the Gly–Xaa–Yaa collagen repeat. Arrows show
potentially ﬂexible regions. (B) Structural organisation of
MASPs. Regions that mediate interactions with MBL are
shown in light grey. Regions involved in substrate recognition
are shown in dark grey. The position of the cleavage site for
zymogen activation is marked by an arrow. The solid line
indicates the disulphide bond that links the N- and C-terminal
fragments together following activation. Arrows above the
ﬁgure show potentially ﬂexible regions.
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Before secretion, any surface-exposed, unpaired cysteine
residues are likely to be capped through disulphide
bonding to cysteine. This process is necessary because
free cysteine residues probably act as retention signals
for MBL as they do for many other secreted proteins, so
only those oligomers with no exposed cysteines are
ready for secretion (Wallis and Drickamer, 1999; Jensen
et al., 2005).
Images of MBL obtained by electron microscopy
reveal bouquet-like structures, with rod-like collagen
stems topped by globular CRDs (Lu et al., 1990).
An interruption (Gly–Gln–Gly) in the collagen
Gly–Xaa–Yaa repeat within the N-terminal half of the
collagenous domain introduces a kink causing the stems
to splay apart. Although there is no direct evidence for
ﬂexibility at this site in MBL, visualisation of type IV
collagen chains by electron microscopy shows some
ﬂexible sites, and the positions of these sites correlate
with several sequence interruptions (Mohs et al., 2006).
While all MBLs have a break in the collagenous
domain, some of the ﬁcolins do not (Fujita et al.,
2004). Here, the junction between the cysteine-richdomain and the collagenous domain might serve as a
ﬂexible hinge. The same region might also be ﬂexible in
MBL, although no structural information is available
for this region. The junction between the collagen triple
helix and the a-helical neck region represents a third
potentially ﬂexible region in MBL. Within the collage-
nous domain, each of the three polypeptide chains is
staggered by one residue whereas all three chains
become aligned in the a helical coiled coil, so at the
junction there must be a change in the alignment of the
polypeptide chains. Corresponding regions in type I and
II class A macrophage scavenger receptors are highly
ﬂexible (Resnick et al., 1996), so this junction probably
also allows some degree of movement in MBL. One or
more of the three potentially ﬂexible regions of MBL are
probably very important to allow the conformational
changes that induce complex activation (see below).
Flexibility at the junction between the collagen-like
domain and the neck probably enables the CRDs to
orient as the molecule docks onto a bacterial cell
surface. The subsequent conformational changes gener-
ated at the other end of the molecule cause the subunits
to realign, providing the trigger for MASP activation.
MBLs recognise foreign cells via multivalent interac-
tions with the carbohydrate epitopes commonly found
on pathogens. Each CRD has a single binding site for
monosaccharides such as mannose, fucose or N-acet-
ylglucosamine, which occur only rarely at the terminal
positions of mammalian oligosaccharides on glycopro-
teins and glycolipids but are present in high-density
arrays on many bacterial, fungal and parasitic cells
(Drickamer, 1993). The sugar-binding site is localised
around one of two Ca2+ sites (Weis et al., 1992).
Equatorial hydroxyl groups at the 3- and 4-OH
positions of the sugar residue serve as coordination
ligands for the Ca2+. Additional coordination ligands
are provided by asparagine and glutamic acid residues in
the CRD that also form hydrogen bonds with the 3- and
4-OH groups of the sugar residue. The limited nature of
the contacts between sugar and protein enables MBL to
recognise a broad range of target ligands. Thus, sugars
which have equatorial OH-groups equivalent to those of
the 3- and 4-OH groups of mannose are ligands.
However, galactose and related sugars that have an
axial 4-OH group are not recognised by MBL. The
afﬁnities of CRDs for monosaccharides are typically
weak (1mM) (Iobst et al., 1994). Consequently,
multiple CRD–sugar interactions involving more than
one MBL subunit are necessary for stable binding of
MBL to pathogens and also for complement activation.Structural organisation of MASPs and MAp19
MASPs are homologues of C1r and C1 s of the
classical pathway. They all have the same modular
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Fig. 2. Structures of human MAp19 (top) and the CU-
B1–EGF–CUB2 fragment of rat MASP-2 (bottom). The
probable location of the high-afﬁnity binding sites for MBL
subunits is shown by circles, the diameters of which roughly
correspond to that of a collagen triple helix. Additional low-
afﬁnity sites are probably located on each of the CUB2
domains.
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complement component Clr/Cls, Uegf and bone mor-
phogenic protein 1 (CUB domains), separated by a
Ca2+-binding epidermal growth factor (EGF)-like
domain and followed by two complement control
protein (CCP) modules and a C-terminal serine protease
domain (Schwaeble et al., 2002) (Fig. 1B). MASPs-1 and
-3 are encoded by a common gene through alternative
splicing. They have identical N-terminal domains but
different linker regions and serine protease domains. A
small non-enzymatic protein called MAp19 or sMAP
also associates with lectin–MASP complexes. MAp19 is
an alternatively spliced product of the MASP-2 gene,
consisting of the N-terminal CUB1 and EGF-like
domains of MASP-2.
MASPs normally circulate as zymogens. However,
when lectin–MASP complexes bind to target epitopes on
pathogens, MASPs-1 and -2 activate through autolysis
at a single site within the short linker region between the
CCP-2 module and serine protease domain. The active
protease domain remains attached to the N-terminal
fragment through a single disulphide bond. MASP-3 is
also activated through cleavage of the linker region.
However, the zymogen cannot autoactivate, so is
probably activated through the action of an unidentiﬁed
serum protease (Zundel et al., 2004).
Recently, the structures of the rat CUB1–EGF–CUB2
fragment and human MAP-19 have been solved (Fein-
berg et al., 2003; Gregory et al., 2004) (Fig. 2). In both
structures, lateral association of the CUB1 and EGF-
like domains about a 2-fold symmetry axis creates a
relatively compact dimer arranged in a head-to-tail
conﬁguration with extensive interactions between
the CUB1 and the EGF-like domains in the dimer
interface. The structures of fragments of MASPs
comprising the CCP-2-serine protease domain and
CCP-1–CCP-2-serine protease domain have also been
solved (Harmat et al., 2004; Ga´l et al., 2005). Interest-
ingly, these structures reveal that the comparable
substrate speciﬁcities of MASP-2 and C1s, of the
classical pathway, are realised through different sets of
enzyme–substrate interactions. Comparison of the
active and zymogen forms of MASP-2 has provided
novel structural insight into MASP-2 activation. These
data are reviewed by Peter Ga´l and colleagues in this
edition of Immunobiology, and will not be covered here
(Ga´l et al., 2007).
While the CUB1–EGF and CCP-1–CCP-2 junctions
are probably quasi-rigid, structural and biochemical
evidence suggests that the EGF–CUB2, CUB2–CCP-1
and CCP-2–serine protease junctions are all potentially
ﬂexible (Feinberg et al., 2003; Gaboriaud et al., 2004;
Gal et al., 2005). These sites probably allow the
conformational changes required to bring the two serine
protease domains into close apposition during activa-
tion (Fig. 1).Interactions between MBL and MASPs
MBL binds to MASPs-1, -2 and -3 with afﬁnities in
the nM range (3.2 and 2.6 nM for human MBL–MASP-
1 and MBL–MASP-2, respectively) (Wallis and Dodd,
2000; Thielens et al., 2001). Binding is mediated through
a portion of the collagenous domain of MBL and the N-
terminal domains of the MASP. All three N-terminal
MASP domains (CUB1–EGF–CUB2) are necessary and
sufﬁcient to reproduce the binding properties of the full-
length proteins. The CUB1–EGF domains also bind to
MBL, but with lower afﬁnity than the N-terminal three
domains and full-size proteins. Consequently, MAp19
binds to MBL 5-fold and 10 more weakly than full-
size MASP-2 in human and rat complexes, respectively.Stoichiometry of MBL–MASP complexes
Different MBL oligomers are able to activate
complement, but with different activities (Wallis and
Drickamer, 1999). In rat MBL, puriﬁed trimers and
tetramers of MBL subunits have the highest activities
(1.1870.23 and 0.9570.05 relative to wild-type pro-
tein), followed by MBL dimers (0.2470.06), while single
subunits have no detectable activity (o0.01) (Wallis and
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and tetramers are all functional while single MBL
subunits are not is due largely to the stoichiometry of
complexes, in which MASP dimers have binding sites
for at least two MBL subunits (Chen and Wallis, 2001).
The most likely arrangement (see below) is where each
protomer of the MASP dimer contains a high-afﬁnity
binding site for one MBL subunit. Thus, MBL dimers
bind stably to single MASP dimers whereas trimers and
tetramers can bind up to two MASP dimers, although
1:1 complexes appear to be more stable than 1:2
complexes (Chen and Wallis, 2001; Teillet et al., 2005).
Consequently, dimers, trimers and tetramers can bind
with high afﬁnity to at least one MASP dimer. Although
single MBL subunits also bind to MASPs, the afﬁnities
are 1000-fold lower than the larger MBL oligomers,
hence their low biological activities (Chen and Wallis,
2001).
Differences in the abilities of MBL oligomers to
activate complement are probably due, at least in part,
to their different afﬁnities for MASPs. The CU-
B1–EGF–CUB2 domains of rat MASP-2 bind to
MBL trimers and tetramers with comparable afﬁnities
(afﬁnities relative to wild-type MBL: 1.070.5 and
1.170.5 for MASP-2 and 1.070.5 and 1.370.3 for
MASP-1, respectively), while MBL dimers bind more
weakly (0.7970.21 for MASP-2 and 0.2070.08 for
MASP-1) (Chen and Wallis, 2001). The reason that
MBL trimers and tetramers bind to MASPs more tightly
than MBL dimers is not known. However, one
possibility is that each protomer of the MASP dimer
contains an extra low-afﬁnity binding site for an
MBL subunit in addition to the high-afﬁnity site
already described, giving a total of four subunit-binding
sites (two high- and two low-afﬁnity sites) per
MASP dimer (Teillet et al., 2006). Consequently, MBL
trimers and tetramers would bind to one or both of the
low-afﬁnity sites as well as to both of the high-afﬁnity
sites.
While the stoichiometry of MBL oligomers binding to
each MASP has been determined, the composition of
circulating MBL–MASP complexes is still unknown.
MASPs-1 and -2 do not interact with each other in
the absence of MBL (Chen and Wallis, 2001). However,
the larger MBL oligomers can potentially bind more
than one MASP, so in vivo these oligomers might
circulate bound to two different MASPs or one MASP
together with MAp19. Analysis of human serum
tentatively supports this suggestion, because larger
MBL oligomers appear to associate with MASP-2 and
MASP-3, while smaller MBL oligomers bind to MAp19
and MASP-1, although the composition of complexes is
not known (Dahl et al., 2001). Thus, it is possible that
certain complexes form preferentially because they are
stabilised through cooperative interactions between
components.Ca2+ dependence of MBL–MASP interactions
The interaction between MBL and MASPs is Ca2+
dependent. The critical Ca2+ sites are probably located
within the CUB1–EGF fragment of the MASPs. In both
of the crystal structures available, a single Ca2+ (site I)
is bound near the N-terminal end of the EGF-like
domain of each protomer, with 4 and 6 conserved
coordination ligands contributed by the protein in the
CUB1–EGF–CUB2 and Map19 structures, respectively.
While dimerisation occurs even in the presence of
chelators and is thus probably Ca2+ independent,
several residues, which lie in or near the Ca2+ site,
participate in interactions with the CUB1 domain of the
adjacent protomer, stabilising the dimer.
In the structure of human MAp19 (and also in C1s
(Gregory et al., 2003)), a second Ca2+ (site II) is bound
to the distal end of each CUB1 module, through ﬁve
protein ligands and a water molecule (Gregory et al.,
2004). Signiﬁcantly, the residues that provide these
coordination ligands are completely conserved in rat
MASP-2 (Fig. 3), although some of these residues are
disordered in the rat structure and no Ca2+ is seen
(Feinberg et al., 2003). Given the sequence identity
between the human and rat proteins, it is likely that a
Ca2+ does normally bind to the CUB1 module of rat
MASP-2 in solution, but the site was not occupied to a
signiﬁcant extent in the crystal structure, probably
because of chelation by tartrate, which was a component
of the crystallisation buffer. As site I is occupied in the
rat structure but site II is not, the afﬁnity of Ca2+ for
site II in the free MASP molecule is probably weaker
than for site I. Interestingly, sequence alignments reveal
that four out of the ﬁve residues that provide coordina-
tion ligands for Ca2+ in CUB1 of Map19 are also
present in equivalent positions in CUB2 (Fig. 3),
implying that this CUB domain might also bind Ca2+.
Analysis by isothermal titration calorimetry shows that
Ca2+ binds to rat MASP-2 CUB1–EGF–CUB2 fragment
with a Kd of 6.372.6mM (Feinberg et al., 2003).
Additional, weaker binding was also detected; however,
this was concomitant with precipitation of the protein at
higher concentrations of Ca2+. The Ca2+ dependence of
MBL binding by the CUB1–EGF–CUB2 fragment was
also 6.3mM, measured by analytical ultracentrifugation.
Thus, the interaction between MASP-2 and MBL might
depend on the single Ca2+ measured by calorimetry.
However, it is not clear whether Ca2+ was binding to site
I or II in these experiments and the afﬁnity for Ca2+ at
one or both sites might change when MASP-2 binds to
MBL, so further studies are required to clarify the roles
of Ca2+ in the MASPs.
Interestingly, additional evidence about the Ca2+
dependence of MBL–MASP binding comes from recent
studies of MASP-2 deﬁciency (Stengaard-Pedersen
et al., 2003; Sorensen et al., 2005). The only individual
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Fig. 3. Aligned sequences of the CUB and EGF domains of MASP-2 and MASP-1/3. Residues providing coordination ligands for
Ca2+ in the EGF (site I) and CUB1 domains (site II) of human Map19 are marked by (B) and (m), respectively. In the rat
CUB1–EGF–CUB2 structure the only coordination ligands observed in the structure are provided by main chain carbonyl oxygen
atoms of Val120 and Tyr140 and the side chains of Asp119 and Asn139. Residues proposed to form part of the binding site for MBL
in the CUB1 domain of human Map19 are indicated by (#). The position of the asparagine residue that is hydroxylated on the b
carbon within the EGF-like domain of rat MBL is marked by (J). Residues at key positions that are identical to those in human
MASP-2 are shaded.
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immunodeﬁciency and autoimmune reactions. The
protein encoded by the MASP-2 gene contains a single
mutation at position 105 in the mature polypeptide, in
which the aspartic acid of the wild-type sequence is
replaced by glycine. Serum MASP-2 levels are lower
than normal and the protein that is present fails to
associate with MBL or ﬁcolins. Normally, Asp105
provides one of the ligands for Ca2+ at site II in the
CUB1 domain (Fig. 3), so a likely explanation for
the observed phenotype is that the mutation reduces the
ability of the MASP to bind Ca2+ at site II, suggesting
that this Ca2+ is critical for MBL binding. Conﬁrmation
of this theory, however, awaits additional studies.
Site-directed mutagenesis of MAp19 indicates that the
high-afﬁnity binding site for MBL is probably located at
the distal end of the CUB1 domain (Fig. 2), near Ca2+
site II (Gregory et al., 2004). The head-to-tail arrange-
ment of protomers in the MASP dimer means that each
protomer is able to bind to a separate MBL subunit
through equivalent interactions. Signiﬁcantly, residues
identiﬁed as putative contacts for MASP-2 are con-
served in rat MASP-2 and are also largely present in
human and rat MASP-1 (Fig. 3). Thus, it is likely that
the MBL-binding sites are equivalent in the human and
rat proteins and that all three MASPs bind to MBL
through at least some comparable contacts.MASP binding to the collagenous domain of MBL
The binding site for MASPs is located within the
collagen-like domain of MBL, beyond the interruptionin the Gly–Xaa–Yaa collagen repeat (Wallis et al.,
2004). Sequence alignment of MBLs and ﬁcolins from a
variety of species reveals the presence of a common
MASP-binding motif: Hyp–Gly–Lys–Xaa–Gly–Pro,
where Hyp is 4-hydroxyproline and Xaa is an aliphatic
amino acid residue other than glycine (Fig. 4). Replace-
ment of the lysine and aliphatic residues (leucine in rat
MBL) with proline and hydroxyproline (stabilising
substitutions in collagen) in rat MBL completely
abolishes its ability to bind to MASPs or activate
complement (Wallis et al., 2004). While one or both
of these residues are essential for binding to all
three MASPs, adjacent residues appear to modulate
binding but to different extents in MASP-1/-3 and
MASP-2. Thus, while the MASP binding sites on MBL
overlap, they are probably not identical. Interestingly,
although the MASP-binding sites themselves do not
contain glycosylated 5-hydroxylysine residues, they are
ﬂanked by glycosylated residues, suggesting that one
function of glucosylgalactosyl-5-hydroxylysine in col-
lagen might be to prevent non-speciﬁc interactions with
other macromolecules.
By combining the available structural and biophysical
data, a model can be created of a minimal functional
MBL–MASP complex in which each MASP dimer
bridges two MBL subunits, through identical interac-
tions between each protomer of the dimer and the
collagen-like domain of a separate MBL subunit. This
binding arrangement allows the CCP and serine
protease domains of the MASP to occupy the space in
between MBL subunits in the middle of the cone-shaped
MBL oligomer, with enough room to permit conforma-
tional changes required to activate the protease upon
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Fig. 4. Proposed location of MASP-binding sites within the collagenous domain of MBL and ﬁcolins. Top, domain organisation of
MBLs and ﬁcolins highlighting the positions of the MASP binding sites and potential glycosylation sites. Bottom, aligned sequences
of human and rat MBLs and ﬁcolins. The consensus motif for MASP binding present in MBLs and ﬁcolins is shaded. Positions of
hydroxyproline (O) and glycosylated hydroxylysine (K) residues are based on the sequences of rat MBLs, in which all proline and
lysine residues at the third position of the Gly–Xaa–Yaa are at least partially modiﬁed, with the exception of the proline residue in
repeat 5, which was completely unmodiﬁed by Edman degradation (Wallis and Drickamer, 1997; Wallis and Drickamer, 1999).
R. Wallis / Immunobiology 212 (2007) 289–299 295binding of MBL to a cell surface (Fig. 5) (Feinberg et al.,
2003). The extra subunits of MBL trimers and tetramers
probably also bind to the MASP through a second lower
afﬁnity binding site located on the CUB2 domain of
each protomer.
The lectin and classical pathways of complement
are closely related with respect to both the structures
and functions of their components (Wallis, 2002a;
Gaboriaud et al., 2004; Sim and Tsiftsoglou, 2004).
Indeed, in vitro studies have shown that larger MBL
oligomers bind and activate C1r2C1s2 complexes, the
protease components of the classical pathway and
homologues of MASPs (Lu et al., 1990). Although not
thought to occur in vivo, these interactions raise
the possibility that MBL and C1q bind and activate
their respective proteases through somewhat compar-
able mechanisms. While mammalian C1q is a hetero-
ligomer, assembled from three different polypeptides
and MBL is homooligomeric, alignment reveals that
sequences akin to MASP-binding sites occur at equiva-
lent positions in all three chains of human C1q (Fig. 4).These regions might represent binding sites for
C1r2C1s2 complexes.MASP activation by MBL
Kinetic studies have shown that MBL activates
MASP-2 by increasing the rate of autocatalysis when
it binds to an activating surface (Chen and Wallis, 2004).
Although relatively little is known about the conforma-
tional changes that follow pathogen recognition, no
signiﬁcant changes occur upon sugar binding by isolated
CRDs or to the neck and CRD fragments of MBL (Weis
et al., 1992; Ng et al., 2002), so a mechanism in which
the signal is transmitted to the MASP through
individual subunits can be largely ruled out. The most
likely activation mechanism is where binding of
MBL–MASP complexes to a bacterial surface induces
a change in the relative arrangement of MBL subunits.
As MASPs span MBL subunits by binding to rod-like
ARTICLE IN PRESS
Fig. 5. Model of MASP activation by MBL. Left, MASP dimer bridges two MBL subunits (the outermost subunits in this example)
through equivalent interactions between each protomer of the MASP and the collagen-like domain of separate MBL subunits.
Middle, binding to a bacterial surface induces a change in the angle between MBL subunits, leading to a change in the conformation
of the MASP, increasing the likelihood of reciprocal cleavage of the linker region of one MASP protomer by the protease domain of
the other. Right, the protease is then locked into the activated conformation and is able to cleave and activate its downstream
substrates.
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joints, engagement of a cell surface by two or more
trimeric lectin heads probably imparts changes to these
joints, which are transmitted to the bound protease
(Fig. 5). Subsequent conformational changes at the
ﬂexible regions of the MASP align the serine protease
domains so that the catalytic site of one protomer
can access the linker region of its partner. Reciprocal
cleavages of the MASP polypeptides ﬁx the protease
domains in the active conformation, enabling recogni-
tion and activation of downstream substrates to initiate
the reaction cascade. Details of such mechanisms
must await further structural analysis of MBP–MASP
complexes.MBL activation and immunodeﬁciency
Three separate mutations in the gene encoding human
MBL are each associated with a common immunode-
ﬁciency (Turner, 1996). The resulting amino acid
substitutions in MBL (Arg32-Cys, Gly35-Asp and
Gly37-Glu) are all located within the N-terminal
portion of the collagenous domain, before the interrup-
tion in the Gly–Xaa–Yaa repeat. Originally, immuno-
deﬁciency was believed to be caused by low levels of
MBL in serum (Super et al., 1989; Lipscombe et al.,
1992). However, recent work has shown that serum
MBL levels are typically only slightly reduced in
individuals with variant alleles, but that the resulting
MBLs have reduced abilities to activate complement
(Garred et al., 2003). The confusion regarding the
underlying cause of the immunodeﬁciency probably
arose because the antibodies traditionally used to
capture MBL from serum preferentially recognise the
larger MBL oligomers associated with wild-type MBL
alleles, while the smaller oligomers present in the serum
of individuals with variant alleles are relatively poorlydetected. Although not providing a reliable measure of
MBL serum concentrations, these antibody-based as-
says are nevertheless still very useful for disease
association studies, because the amounts of MBL
detected in plasma samples appear to correlate closely
with their abilities to activate the lectin pathway.
Nevertheless, use of the terms ‘MBL levels’ and ‘MBL
concentrations’ to describe the results of such assays is
misleading. In particular, because MBL is believed to be
an opsonin in addition to its role in complement
activation, and the effects of the MBL mutations on
this and other functions is not known.
Studies using human and rat recombinant MBLs to
investigate the molecular basis of the disorders reveal
that each mutation causes a change in the composition
of MBL oligomers in the encoded protein, resulting in
fewer of the larger oligomers and more of the smaller
oligomers (Super et al., 1992; Wallis and Cheng, 1999;
Larsen et al., 2004). In the Arg-Cys variant, the defect
is probably caused by adventitious disulphide bond
formation, involving the introduced cysteine residue,
which impairs assembly of subunits during biosynthesis.
The consequent reduction in the ability of rat MBL
containing the equivalent mutation to activate comple-
ment can be explained entirely by the change in the
distribution of oligomers, the smaller oligomers (pre-
dominantly monomers and dimers of subunits) having
lower intrinsic activities than the larger oligomers
(trimers and tetramers of subunits) (Wallis and Cheng,
1999).
Defective oligomerisation in the glycine variants is
caused by disruption to the collagen triple helix through
incorporation of the bulky acidic side chains. Studies
using synthetic collagen peptides have shown that Gly-
Asp/Glu substitutions are highly destabilising to
helix formation (Persikov et al., 2004). When introduced
into rat MBL, these mutations reduce the melting
temperature of the collagenous domain from 47 to
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associate to some extent during biosynthesis, fewer of
the larger oligomers are formed. Consequently, the
defect can partly be explained by defective oligomerisa-
tion (Wallis and Cheng, 1999). Nevertheless, activities of
recombinant MBLs containing equivalent mutations are
still lower than would be expected, even accounting for
differences in the composition of oligomers between
variant and wild-type proteins. Here, the additional
defect is caused mainly by failure of variant
MBL–MASP complexes to activate upon binding to a
target carbohydrate ligand (Wallis et al., 2005). Decou-
pling of carbohydrate binding and MASP activation by
the variant MBLs is probably caused by increased
ﬂexibility in the N-terminal part of the collagenous
domain, preventing the conformational changes that
trigger MASP activation.
All three mutations to the collagenous domain of
MBL have dominant or partially dominant phenotypes.
The basis of these phenotypes has also been investigated
in recombinant systems by co-expressing wild-type and
variant MBL polypeptides in the same cell line (Wallis,
2002b). These studies show that MBLs are secreted
almost exclusively as hetero-oligomers containing wild-
type and variant polypeptides, which are defective in
activating the complement cascade. Analogous domi-
nant-negative phenotypes would also explain the im-
munodeﬁcient phenotypes of individuals heterozygous
for variant MBL alleles.
Studies using recombinant proteins are extremely
useful for helping us understand the molecular defects
associated with the variant MBL alleles. However, the
situation in vivo is more complex because interactions
with other molecules can alter the make-up of circulat-
ing complexes. For example, MBL oligomers assembled
from variant alleles are more susceptible to proteolysis
by matrix metalloproteinases than wild-type MBL
(Butler et al., 2002). Proteolysis in vivo might reduce
the concentration of circulating protein and also alter
the composition of oligomers in the serum. Differences
in the rates of biosynthesis might also affect the levels of
proteins in serum. Indeed, MBL containing either of the
glycine mutations is secreted more slowly than wild-type
MBL due to changes during biosynthesis, which might
contribute to the somewhat reduced MBL levels in vivo
(Heise et al., 2000).Concluding remarks
In conclusion, considerable progress has been made in
characterising the interactions between MBL and
MASPs through a combination of structural and
biochemical analysis of protein fragments and molecular
biological approaches. By combining the available data,models of MBL–MASP complexes have been generated
and will be further reﬁned by experimentation. Never-
theless, the molecular details of the interaction mechan-
isms require further structural studies of MBL–MASP
complexes. Given the heterogeneity and probable
ﬂexibility of MBL and MASPs, crystallographic analysis
of full size complexes is likely to be extremely challen-
ging, so the use of smaller complexes assembled from
protein fragments might be the best way to proceed.
The ultimate objective of this research requires
understanding of the structural changes that occur upon
activation of the MBL–MASP complex. A major
drawback is that complement activation requires an
activating surface such as a bacterial cell wall, making
structural analysis of complexes very difﬁcult to achieve.
One strategy that we are currently using to circumvent
this problem is to trap complexes in different activation
states using MBLs or MASPs containing mutations
at activation-sensitive sites. In this way it should
be possible to analyse the activation process, even
in the absence of a carbohydrate target. Hopefully,
future structural and functional analysis of suitable
complexes will provide novel insights into the activation
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